Ansun Biopharma, Inc.
11568 Sorrento Valley Road
About Ansun Biopharma, Inc.
Who We Are
Ansun is leading the development of novel therapeutics to address unmet needs in viral disease and cancer by using its industry-leading expertise in sialic acid biology.
We are industry veterans with significant drug discovery, development and commercialization expertise. We share a vision of developing innovative products to save lives, especially for vulnerable and underserved patients.
We focus our drug development programs to directly target unmet medical needs.
Our lead product, DAS181, is a sialidase fusion protein that removes the sialic acid present on the host cell surface that certain viruses use to enter the cell;it was conceived and designed using knowledge of virus and host interaction and sialic acid biology. DAS181 is now undergoing a Phase 3 clinical trial for the treatment of human Parainfluenza Virus (“PIV”) in immunocompromised patients.
Leveraging Ansun’s deep knowledge of sialic acid biology, we develop state-of-the-art multi-modality therapeutics for the treatment of cancer. This has led to programs including oncolytic virus, tumor microenvironment (TME)-modulating bispecific antibodies, and tumor-targeting CAR-NK/γδ T cells.
15 articles with Ansun Biopharma, Inc.
Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the company will present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, taking place September 14-16.
Ansun Biopharma to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. The company will deliver a corporate update to potential investors and strategic partners, among other various relevant audiences. The corporate update will cover recent and upcoming Company milestones, as well as detail clinical progress of the Company
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
Ansun Biopharma Enrolls First Patient in Proof of Concept Trial of DAS181 for the Treatment of COVID-19
New study will build on recent clinical evidence showing efficacy of DAS181 in improving symptoms of patients with severe COVID-19
Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment
Treatment with DAS181, a clinical-stage recombinant biologic, reduced or eliminated the need for supplemental oxygen, and improved key patient vital signs
China's NMPA Approves Two Separate INDs On The Same Day For Ansun's Investigational Biologic Compound DAS181
Ansun Biopharma, Inc., a clinical stage biopharmaceutical company headquartered in San Diego, CA, today announced two major international regulatory milestones being achieved simultaneously.
Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection
Ansun Biopharma, Inc., announced that the first patient has been enrolled in its Phase 3 clinical trial evaluating the efficacy and safety of DAS181 for the treatment of hospitalized, immunocompromised patients with lower respiratory tract parainfluenza virus infection.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Ansun Biopharma, Inc., today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
Ansun Biopharma is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral infections,
Ansun is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections.
Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181.
Ansun BioPharma Announces Two Publications Showing Inhibitory Effects Of DAS181 On Respiratory Syncytial Virus (RSV) And Human Metapneumovirus (hMPV)